Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonism.
There is clearly a necessity to identify novel non-dopaminergic mechanisms as new therapeutic targets for Parkinson's disease (PD). Among these, the soluble guanylyl cyclase (sGC)-cGMP signaling cascade is emerging as a promising candidate for second messenger-based therapies for the ameliorati...
Main Authors: | Kuei Y Tseng, Adriana Caballero, Alexander Dec, Daryn K Cass, Natalie Simak, Elizabeth Sunu, Michael J Park, Shannon R Blume, Stephen Sammut, Diana J Park, Anthony R West |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3206945?pdf=render |
Similar Items
-
Particulate Guanylyl Cyclase A/cGMP Signaling Pathway in the Kidney: Physiologic and Therapeutic Indications
by: Yang Chen, et al.
Published: (2018-03-01) -
Guanylyl Cyclase A/cGMP Signaling Slows Hidden, Age- and Acoustic Trauma-Induced Hearing Loss
by: Philine Marchetta, et al.
Published: (2020-04-01) -
Correction: The Receptor-Bound Guanylyl Cyclase DAF-11 Is the Mediator of Hydrogen Peroxide-Induced cGMP Increase in.
by: Ulrike Beckert, et al.
Published: (2013-01-01) -
The role of pedunculopontine region in basal ganglia mechanisms of akinesia
by: Munro-Davies, Lisa Edana
Published: (1999) -
Guanylyl Cyclase-cGMP Signaling Pathway in Melanocytes: Differential Effects of Altered Gravity in Non-Metastatic and Metastatic Cells
by: Krassimira Ivanova, et al.
Published: (2020-02-01)